One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Focus on trials: dementia, lipids, thrombosis, and heart failure
Filippo Crea
doi : 10.1093/eurheartj/ehac746
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 4965–4969
Future technologies in total artificial heart development: can a robot become as good as a donor heart?
Maziar Arfaee, Annemijn Vis, Jolanda Kluin
doi : 10.1093/eurheartj/ehac512
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 4970–4972
Heart Failure Association/European Society of Cardiology Atlas second edition: new insights into understanding the burden of heart failure
Petar M Seferović, Giuseppe M C Rosano, Panos Vardas, Ivan Milinković, Marija Polovina, Adam Timmis, Andrew J S Coats
doi : 10.1093/eurheartj/ehac513
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 4973–4975
Long QT syndrome: long story short
Jin Li
doi : 10.1093/eurheartj/ehac551
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 4976–4977
Fractional flow reserve or intravascular ultrasound for guiding percutaneous coronary intervention of intermediate coronary stenoses? Sometimes apples and oranges have the same FLAVOUR
Rocco Vergallo, Massimo Volpe
doi : 10.1093/eurheartj/ehac595
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 4978–4979
Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis
Ruth Peters, Ying Xu, Oisin Fitzgerald, Htein Linn Aung, Nigel Beckett, Christopher Bulpitt, John Chalmers, Francoise Forette, Jessica Gong, Katie Harris, Peter Humburg, Fiona E Matthews, Jan A Staessen, Lutgarde Thijs, Christophe Tzourio, Jane Warwick, Mark Woodward, Craig S Anderson, Dementia rIsk REduCTion (DIRECT) collaboration
doi : 10.1093/eurheartj/ehac584
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 4980–4990
Observational studies indicate U-shaped associations of blood pressure (BP) and incident dementia in older age, but randomized controlled trials of BP-lowering treatment show mixed results on this outcome in hypertensive patients.
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Faiez Zannad, João Pedro Ferreira, Javed Butler, Gerasimos Filippatos, James L Januzzi, Mikhail Sumin, Matthias Zwick, Maral Saadati, Stuart J Pocock, Naveed Sattar, Stefan D Anker, Milton Packer
doi : 10.1093/eurheartj/ehac495
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 4991–5002
Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse patient populations, but their mechanism of action requires further study. The aim is to explore the effect of empagliflozin on the circulating levels of intracellular proteins in patients with heart failure, using large-scale proteomics.
SGLT2 inhibitors in heart failure: insights from plasma proteomics
Clemens Gutmann, Thomas A Zelniker, Manuel Mayr
doi : 10.1093/eurheartj/ehac624
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5003–5005
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
Marco Metra, Matteo Pagnesi, Brian L Claggett, Rafael DÃaz, G Michael Felker, John J V McMurray, Scott D Solomon, Diana Bonderman, James C Fang, Cândida Fonseca, Eva Goncalvesova, Jonathan G Howlett, Jing Li, Eileen O’Meara, Zi Michael Miao, Siddique A Abbasi, Stephen B Heitner, Stuart Kupfer, Fady I Malik, John R Teerlink
doi : 10.1093/eurheartj/ehac293
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5006–5016
Patients with heart failure with reduced ejection fraction and low systolic blood pressure (SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical treatment. Omecamtiv mecarbil may be particularly helpful in such patients.
Omecamtiv mecarbil for patients with severe systolic dysfunction and hypotension
Maria Generosa Crespo-Leiro, Theresa A McDonagh, Eduardo Barge-Caballero
doi : 10.1093/eurheartj/ehac552
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5017–5019
Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry
Joel P Giblett, Andrija Matetic, David Jenkins, Choo Y Ng, Shreenidhi Venuraju, Tobias MacCarthy, Jonathan Vibhishanan, John P O’Neill, Bilal H Kirmani, D Mark Pullan, Rod H Stables, Jack Andrews, Nicolas Buttinger, Wan Cheol Kim, Ritesh Kanyal, Megan A Butler, Robert Butler, Sudhakar George, Ayush Khurana, David S Crossland, Jakub Marczak, William H T Smith, John D R Thomson, James R Bentham, Brian R Clapp, Mamta Buch, Nicholas Hayes, Jonathan Byrne, Philip MacCarthy, Suneil K Aggarwal, Leonard M Shapiro, Mark S Turner, Joe de Giovanni, David B Northridge, David Hildick-Smith, Mamas A Mamas, Patrick A Calvert
doi : 10.1093/eurheartj/ehac511
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5020–5032
Post-infarction ventricular septal defect (PIVSD) is a mechanical complication of acute myocardial infarction (AMI) with a poor prognosis. Surgical repair is the mainstay of treatment, although percutaneous closure is increasingly undertaken.
Management of post-infarction ventricular septal defects: are we moving forward?
Fernando Alfonso, Rio Aguilar, Guillermo Reyes
doi : 10.1093/eurheartj/ehac532
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5033–5036
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54
Marc P Bonaca, KyungAh Im, Giulia Magnani, Sameer Bansilal, Mikael Dellborg, Robert F Storey, Deepak L Bhatt, P Gabriel Steg, Marc Cohen, Per Johanson, Eugene Braunwald, Marc S Sabatine
doi : 10.1093/eurheartj/ehac402
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5037–5044
In patients with prior myocardial infarction (MI) on aspirin, the addition of ticagrelor reduces ischaemic risk but increases bleeding risk. The simultaneous assessment of baseline ischaemic and bleeding risk may assist clinicians in selecting patients who are most likely to have a favourable risk/benefit profile with long-term ticagrelor.
Platelet antiaggregation after an acute coronary syndrome: what about the elderly?
Kurt Huber
doi : 10.1093/eurheartj/ehac405
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5045–5046
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Kausik K Ray, David Kallend, Lawrence A Leiter, Frederick J Raal, Wolfgang Koenig, Mark J Jaros, Gregory G Schwartz, Ulf Landmesser, Lorena Garcia Conde, R Scott Wright, ORION-11 Investigators
doi : 10.1093/eurheartj/ehac615
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5047–5057
Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic proprotein convertase subtilisin/kexin type 9 production, in primary prevention patients with elevated LDL-C despite statins.
Inclisiran in primary prevention: reality or fiction?
Baris Gencer, François Mach
doi : 10.1093/eurheartj/ehac653
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5058–5060
dal-GenE was negative—not positive except for COVID-19
Allan D Sniderman
doi : 10.1093/eurheartj/ehac637
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Page 5061
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome
Jean-Claude Tardif, Marc A Pfeffer, Marie-Pierre Dubé, dal-GenE Investigators
doi : 10.1093/eurheartj/ehac644
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Pages 5062–5063
Unexpected find of native aortic leaflet thrombus during surgical myocardial revascularization
Erwan Salaun, Jacques Villeneuve, Pierre Voisine
doi : 10.1093/eurheartj/ehac589
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Page 5064
Growing giant coronary artery aneurysm
Daisuke Fukamachi, Yasuo Okumura
doi : 10.1093/eurheartj/ehac639
European Heart Journal, Volume 43, Issue 48, 21 December 2022, Page 5065
